Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Targeted Therapy 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Cholangiocarcinoma 1

Interventions

Temozolomide 43Magnetic Resonance Spectroscopy 41Radiotherapy 23Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6pembrolizumab 5abemaciclib 5Standard of Care 5Lomustine 5ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4vorasidenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × olutasidenib × 1 year × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡